AffiliationLaboratory Medicine Academic Group, Medical School, University of Manchester, Manchester, UK. Mqbssbg5@fs1.scg.man.ac.uk
MetadataShow full item record
AbstractCD105 (endoglin) is an important component of the transforming growth factor-beta (TGF-beta) receptor complex and is highly expressed in endothelial cells in tissues undergoing angiogenesis such as healing wounds, infarcts and in a wide range of tumours. In an attempt to understand the molecular mechanism by which CD105 exerts its effects on angiogenesis by modulating TGF-beta1 signalling, in this preliminary communication, CD105 transfected rat myoblasts were utilized as an in vitro model. Overexpression of CD105 in these transfectants antagonised TGF-beta1-mediated inhibition of cell proliferation and reduced TGF-beta1-mediated p3TP-Lux (PAI-1 promoter) luciferase activity. It also reduced (CAGA)12-Luc luciferase activity in response to TGF-beta1. The CAGA sequence is specific for Smad3/4 binding, implying that CD105 is involved in inhibition of TGF-beta1/Smad3 signalling. Furthermore, CD105 overexpression reduced serine phosphorylation of Smad3 and inhibited subsequent nuclear translocation of Smad3. CD105 resulted in high phosphorylation of JNK1, which is able to activate c-Jun. c-Jun is known to inhibit Smad3 transcriptional activity on CAGA sites, suggesting that CD105 may also inhibit Smad3 signalling through JNK1.
CitationCD105 inhibits transforming growth factor-beta-Smad3 signalling., 24 (3a):1337-45 Anticancer Res.
- Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells.
- Authors: Warrington K, Hillarby MC, Li C, Letarte M, Kumar S
- Issue date: 2005 May-Jun
- Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis.
- Authors: Arnulf B, Villemain A, Nicot C, Mordelet E, Charneau P, Kersual J, Zermati Y, Mauviel A, Bazarbachi A, Hermine O
- Issue date: 2002 Dec 1
- Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
- Authors: Song K, Cornelius SC, Reiss M, Danielpour D
- Issue date: 2003 Oct 3
- The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
- Authors: Poncelet AC, de Caestecker MP, Schnaper HW
- Issue date: 1999 Oct
- c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity.
- Authors: Dennler S, Prunier C, Ferrand N, Gauthier JM, Atfi A
- Issue date: 2000 Sep 15